The Earth Optimization Prize: A Standing Market for the Least Bad Idea in the World
Two Terminal Metrics, Three Instruments, and a Prize Pool That Releases When People Actually Stop Dying
Abstract
Current governance mechanisms allocate trillions of dollars based on lobbying intensity, institutional inertia, and political convenience rather than verified outcomes. This paper proposes a standing prize funded by three complementary instruments: Incentive Alignment Bonds (IABs) for investors (capital funds the lobbying campaign; pro-rata revenue share of treaty funding flows on success at 272% annual return); PRIZE tokens for philanthropists and speculators (deposit back plus interest on failure, pool distributed to VOTE holders on success); and VOTE tokens earned by recruiters (transferable proof of how many verified participants you brought into the coalition). IAB bond price, PRIZE token price, and VOTE token price are three real-time, money-backed signals of system health. Every bondholder is financially incentivized to recruit voters, lobby politicians, and fund implementation work, because all of these raise bond value. Every VOTE holder is incentivized to recruit, because recruitment earns tokens worth a share of the PRIZE pool. The treasury releases funds proportionally as two terminal welfare metrics (median healthy life years and median real after-tax income) improve in adopting jurisdictions. The mechanism is compatible with public choice theory: no actor is asked to become less selfish; stronger self-interest makes the system stronger. The Earth Optimization Plan v1 is, by any honest assessment, objectively terrible. It is the starting benchmark, not the goal. The prize exists to discover and cause the implementation of whatever beats it: the Earth Optimization Plan v2. There are 8 billion of you and AIs that are almost certainly smarter than its authors. Finding something better should not be difficult.
The Earth Optimization Plan v1 is the terrible starting benchmark. The prize exists to find whatever beats it (the Earth Optimization Plan v2) and cause that implementation instead. The point is not to marry a blueprint. The point is to stop subsidizing death, disease, waste, and suffering. We are not sure why your civilization does not already have a machine like this.
To be clear about what is strange here: every constitution on your planet already says the goal of government is to maximize the general welfare. Your species has been on this rock for millions of years. You have had written law for thousands of them. And in all that time, nobody built a machine that measures whether the general welfare is actually being maximized, scores proposals on whether they improve it, and funds whichever one wins. Instead, the primary activity of your governments is funneling wealth to interest groups, terrorizing immigrants, and bombing people of different colors, and the secondary activity is writing eloquent constitutions explaining why they would never do that. The prize is an absurd workaround. It should not be necessary to attach financial incentives to the goal of not killing people in order to get anyone to pay attention to it for more than five seconds. And yet here we are, designing an elaborate mechanism to remind your species of the thing it already wrote down and then immediately ignored. We find this very puzzling.
The cost of the current approach is not abstract. 150 thousand deaths/day people die of treatable disease every day. 102 million have already died waiting for drugs that were proven to work but stuck in regulatory queues. The annual economic burden of treatable disease runs $400T. The total opportunity cost of political dysfunction (the gap between what governance delivers and what it could deliver) is $101T per year. Those are not projections. They are the running tab for not having a mechanism that selects and implements better ideas.
And those are just the static costs. The trajectory is worse. Your destructive economy (military spending beyond deterrence plus cybercrime) is already 11.5% of GDP and growing faster than the productive economy. The Soviet Union collapsed at 15% military spending alone, with worse technology and a smaller parasitic sector. At the crossover point, the rational choice for any individual, company, or nation flips from “build things” to “steal things”; you have a name for places where this already happened, and it is “failed states.” At current growth rates, your destructive economy hits 50% in 15 years. There is no Colombia to flee to when the global economy is the failed state. The loop that drives it (print money, fund military, devalue wages, push talent toward cybercrime, justify more military spending) is self-reinforcing. It does not stop on its own. Something has to break it.
We noticed that policy design on Earth works like a philosophy seminar: interesting discussions, no binding output. An engineering competition would at least produce prototypes.
ImportantDisqualification Rule
If your proposal requires politicians, bureaucrats, investors, regulators, voters, or interest groups to become less selfish than they currently are, you have described a pleasant world rather than a mechanism for reaching it. “Requires selflessness” is not the same as “makes self-interest coincide with better outcomes.” The prize accepts contributions that are rational expected-value bets (the break-even probability shift is tiny) and can optionally be structured as assurance contracts with downside protection. That is mechanism design, not altruism. We have been observing your species since 1945 and have not yet seen selfishness decline on request.
Why Current Systems Fail
One of your economists noticed this in 1965 and named it “the logic of collective action”137. The observation: concentrated interests (defense contractors, entrenched pharmaceutical monopolies, legacy energy conglomerates) face high per-capita stakes in policy outcomes, so they easily overcome coordination costs to fund sustained lobbying. Diffuse beneficiaries (the general public dying of untreated diseases, bearing the cost of regulatory delay, or subsidizing low-return military spending) have tiny individual stakes in any single policy fight and cannot coordinate a proportional response. Your species identified the exact mechanism by which your governance fails, published it, gave it a name, assigned it in universities, and then continued to be governed by it for sixty years.
This keeps happening even though the public has far more money. Global household wealth totals $454T, compared to $5T held by concentrated opposition sectors. The public has the money. It does not have the coordination mechanism. Politicians know which programs have high benefit-cost ratios and which do not. They fund the low-return programs anyway, because right now the concentrated cost of opposing a lobby exceeds the diffuse benefit of pleasing an uncoordinated public138.
Everyone thinks this is crazy because everyone else thinks this is crazy. If every human realized that nearly every other human would like a world without war and disease and an extra $14.9M in lifetime income, it would be done tomorrow and the world would be unrecognizable. Your economists call this pluralistic ignorance. We call it the dumbest reason a civilization has ever continued dying. A cryptographically verified global referendum proves that the support already exists. It does not create demand for not dying. The demand is there. The referendum makes it impossible to pretend it is not.
Army ants navigate by following the ant ahead. When the front meets the back, they circle until they drop. Nobody checks whether anyone actually knows where they are going. Your species does this with “it’ll never work.” (Clemzouzou69, CC BY-SA 4.0)
The prize exists because no existing system solves this, and your species has tried the obvious alternatives. Advance Market Commitments139 say “we will buy the thing if you build it,” which works when the thing is a vaccine but not when the thing is “governance change plus health infrastructure plus income growth simultaneously.” You cannot pre-order systemic reform from a catalog. Challenge prizes (the XPRIZE model) give a fixed payout to the first team across the finish line, then stop paying; your incentive to keep implementing after winning is exactly zero, which is what you get. Direct government procurement funds whatever the procurer thinks will work, which IS the current system, and it IS producing Olsonian capture; the prize exists precisely because the procurer is captured. Prediction markets tell you what will win but do not cause implementation. DAOs suffer the same Olsonian capture: whoever buys the most tokens sets the agenda. A prize with published scoring, adversarial challenges, and automatic replacement is the one structure where capturing it requires beating every challenger on verified metrics simultaneously. That is not capture-proof. But it is capture-expensive, which on your planet is probably the least bad available.
The Mechanism
A normal prize gives someone cash after they do something impressive. That is fine for building a better battery. It is useless for governance reform, because the hard part is not inventing the idea. The hard part is forcing implementation through institutions designed to resist it.
The Earth Optimization Prize works differently. Six moving parts:
1. Three instruments, two campaigns. This is not a charity. It is not a donation. PRIZE tokens and VOTE tokens run the prize. Incentive Alignment Bonds138 (IABs) run the lobbying campaign. The instruments are complementary but separate: the prize and referendum create awareness; IABs convert awareness into political pressure.
PRIZE tokens fund the prize pool. Buyers deposit funds into escrow earning 10% annually via rolling locked stablecoin staking. If, at year 15, global HALE has not reached 79 years and global median income has not reached $504K, buyers get their deposit back plus interest at 4.18x (zero downside). If both targets are met, the entire pool is distributed to VOTE token holders proportional to their holdings. A conditional donation: your money only spends if someone earned it. Philanthropists buy because they want to fund success. Pessimists buy for the risk-free interest. Both grow the prize pool.
VOTE tokens are the allocation mechanism (see Point 4). Recruit a verified referendum participant, earn tokens. On success, VOTE holdings determine your share of the PRIZE pool. The referendum campaign runs on VOTE tokens: because pluralistic ignorance is the primary bottleneck, getting one verified human to publicly say “I want this” is worth more than most policy white papers.
Incentive Alignment Bonds (IABs) fund the lobbying campaign. Same instrument described in the IAB companion paper138. IAB capital pays for scorecards, PACs, legislative drafting, and post-office career guarantees for politicians who champion the treaty. On success, bondholders receive a pro-rata share of 10% of treaty funding flows (272% annual returns). Every bondholder is financially incentivized to lobby politicians, recruit voters, and fund implementation work, because all of it raises implementation probability and therefore bond value. Nobody coordinates the lobbying campaign. The bond price coordinates the lobbying campaign.
The maximum cost of achieving any policy change through legal democratic channels is $1B for the United States and roughly $200B globally, with ROI exceeding 400,000:1 for military-to-health reallocation140. “Political impossibility” is a capital allocation problem, not a physics problem. And every dollar in bonds is a public signal that one more human thinks this is worth funding, which, given that pluralistic ignorance is the primary bottleneck, might be worth more than the dollar itself.
Both PRIZE tokens and IABs are tradable on regulated secondary markets, registered under Reg A+ (up to $75M from anyone, no accredited investor requirement) or equivalent social impact bond frameworks. Holders can sell their position at any time. The market prices are real-time, money-backed estimates of success probability and prize pool value. If IABs trade above par, the market is literally saying “this will probably succeed.” Polls are ignorable. Petitions are ignorable. A secondary market where people are betting real money that diseases will get cured is harder to dismiss, and it gives every skeptic a live price feed showing how many other people disagree with them.
Buying a bond is not required to vote in the global referendum. Voting is free. But for anyone who can buy in, doing so is strictly better than just voting: PRIZE tokens give you downside protection while growing the prize pool; IABs give you a revenue share while funding the lobbying campaign. Either way, your financial signal amplifies your political signal. Two signals, both valuable: referendum headcount tells politicians “this many people will vote you out”; bond market price tells the world “this much money believes it will work.” A politician can dismiss a bond market. A politician can dismiss a referendum. A politician cannot dismiss 280 million voters AND a bond market trading above par simultaneously.
2. Two terminal metrics, two targets. The prize measures exactly two things: median healthy life years (dHealthy_med) and median real after-tax income (gIncome_med). The PRIZE pool releases when both reach the Wishonia trajectory projections at year 15:
Binary trigger: both targets met at year 15, PRIZE pool distributes to VOTE holders. Either target missed, PRIZE holders get refund plus interest. VOTE token holders don’t need a proportional payout mechanism because the secondary market already handles it: as metrics trend toward the targets, probability of hitting the trigger rises, VOTE token price rises, and holders can sell at any point. The secondary market IS the proportional reward. The binary trigger IS the clean assurance contract.
Everything the prize exists to produce is either healthy life years or income. If healthy life years went up, trials worked, money moved, and legislation passed. If income rose, governance reform functioned. Paying separately for budget reallocation or trial enrollment is paying for plumbing that may or may not deliver water. Pay for water. The obvious Goodhart objection: median metrics can be gamed. If the sickest die faster, median health rises. But mortality is binary and hard to fake across millions of people. Median income requires improving the middle of the distribution, not just the top. And the adversarial challenge window means anyone who catches gaming can post a bond, present evidence, and claw back the payout.
3. Treasury releases as metrics improve. Separate from the binary PRIZE pool trigger, the implementation treasury releases funds proportionally as the terminal metrics improve in adopting jurisdictions, verified by peer-reviewed quasi-experimental study or RCT with causal attribution. The method: synthetic controls across staggered-adoption jurisdictions, difference-in-differences with the Optimitron141 running continuous causal inference using the methodology specified in the OPG companion142. The challenge-window mechanism provides adversarial review of attribution claims. Health gets 50%, income gets 50%. Countries sign the treaty at different times; that staggered adoption is your natural experiment, handed to you for free. Signatories vs. non-signatories. That is exactly how PEPFAR was evaluated, except the Optimitron processes incoming data as it arrives rather than waiting for an academic team to form a committee and argue about methodology for three years.
4. VOTE tokens are the allocation mechanism. VOTE tokens are transferable, on-chain proof issued to anyone who recruits a verified participant into the wishocratic allocation or treaty referendum. You recruit someone, you earn tokens. More recruitment, more tokens. When the PRIZE pool distributes on success, it distributes proportional to VOTE holdings. The tokens ARE the allocation; no additional scoring or comparison mechanism required. Whoever recruited the most coalition gets the most prize money. Because pluralistic ignorance is the primary bottleneck, getting one verified human to publicly say “I want this” is worth more than most policy white papers. VOTE tokens are the receipt for doing exactly that.
5. Secondary market as signal. VOTE tokens are tradable. Recruiters can sell early; buyers are betting the plan succeeds and recruitment credit will be valuable. The secondary market price is a live estimate of what recruitment credit is worth. This creates three price signals: IAB bond price (implementation probability), PRIZE token price (prize pool size and success probability), and VOTE token price (recruitment credit value). Each signal is useful to different actors. Together they provide a real-time, money-backed dashboard of the entire system’s health. No appointed judges, no formal ranking formula. The market ranks contributors by how much other people’s money they attracted to the cause.
6. Brief constraints. A proposal is disqualified if it transfers suffering to voiceless populations (foreigners, future people, nonhuman animals) rather than reducing it; fails to cover the required governance functions or replace them with something strictly better; cannot beat the baseline on cost per DALY; or gets weaker when humans act selfishly. One paragraph, not ten sections.
The prize does not defend any particular proposal against better ideas. It uses better ideas to unstick worse ones. If a superior proposal appears, VOTE token holders shift recruitment to it and IAB bondholders redirect lobbying toward it, because both maximize their own returns. Your species will object: “if the incumbent knows a better proposal can steal its funding, why not extract value quickly and leave?” Because the biggest reward is outcome perpetuity, a continuing revenue share that only flows while you keep producing results. Grab the money and run, and you forfeit the perpetuity stream. This is the same reason your restaurant owners do not poison the food and flee with the cash register: the ongoing revenue is worth more than the one-time theft. And if the analogy fails (restaurants have physical location and reputation constraints that prize implementers do not), the replacement rule catches what reputation does not: any implementer who degrades performance gets outcompeted by a challenger claiming the perpetuity stream. Your species figured this out for restaurants. We are applying it to governance.
The protocol itself is replaceable: a strictly better selection mechanism replaces the current one under the same replacement rule. The two numbers don’t change. Everything building toward them is improvable plumbing.
Why the Bond Runs the Lobbying Campaign
The IAB replaces the entire lobbying campaign budget. Without it, the plan requires separate coordination: hire lobbyists, run PACs, fund scorecards, draft legislation. The bond makes all of that emergent. A bondholder who recruits one verified referendum voter has raised implementation probability by some epsilon, which has raised the value of every bond in existence. The bondholder does not need to be told to lobby. They need to own a bond and be greedy. Same for sharing, funding implementation work. The secondary market price is real-time feedback on whether the lobbying campaign is working. The referendum campaign is separate: VOTE tokens reward recruiters for building the coalition, while IABs reward investors for converting that coalition into political pressure.
Your species already built a system like this. Satoshi did not coordinate miners. The block reward made mining the self-interested choice, and the network self-organized. This bond does not coordinate a lobbying campaign. The revenue share makes lobbying the self-interested choice, and the campaign self-organizes. The difference: Bitcoin’s output is a ledger. This bond’s output is a treaty that cures diseases. Same mechanism design. Different product.
Why Attribution Precision Stops Mattering
The obvious objection to Point 3’s causal attribution methodology is that synthetic controls are imperfect and governments will dispute the results to avoid paying. But every actor with power to block or dispute holds bonds. Politicians, bureaucrats, investors, donors; they all own equity in the outcome. If the system starts generating massive wealth and curing diseases, and an academic paper points out that “only 60% of the GDP growth was technically caused by the treaty,” nobody with power is going to care. They are getting paid. They are not dying. They have zero incentive to nitpick the causal model and break the machine that is making them rich. On your planet, nobody audits the golden goose.
Strict causal attribution matters in zero-sum games where budgets are tight. If a government is scraping together $100 million for a pilot, they will fight over whether it “worked.” The scale here is not zero-sum. Military spending returns roughly 0.7:1. Medical research returns 100:1 or better. When a reallocation unlocks trillions in value, there is enough surplus to pay bondholders their revenue share, fund the next round of trials, and still deliver a massive population-wide income gain. When margins are that high, you do not need perfect accounting. You need the directional vector to be unarguably positive. And the staggered adoption design from Point 3 makes the direction unarguable: signatories versus non-signatories is a natural experiment that even a motivated skeptic cannot dismiss.
Why wouldn’t a government cancel the revenue share once reforms are passed? Because canceling the bonds destroys the political machine holding the coalition together. The secondary market collapses. The financial incentive for the decentralized lobbying network vanishes. Politicians lose the PAC funding and voter support generated by bondholders. The system reverts to the old equilibrium, where concentrated interests slowly dismantle the new infrastructure. Every government official who holds bonds (and they all do, because it is the highest-return investment available) would be destroying their own portfolio. Your species has a word for a political coalition whose members are all financially incentivized to keep it alive: “durable.”
The prize is everything above. Two metrics, a payout rule, and a replacement mechanism. That is the entire machine. Everything below is our draft entry (the Earth Optimization Plan v1), which we believe is terrible but better than what your species is currently doing. It exists because competitions need a starting entry. You are invited, and in fact begged, to replace it with something better.
The Starting Benchmark
What follows is our homework. The thing to beat is the integrated set of required functions implied by the companion papers.
Must allocate public-goods spending better on the terminal metrics
Legal and institutional implementation path
Right to Trial & FDA Upgrade Act + treaty/statutory tools
Must create equal or stronger binding force
Narrative, coalition, and sequencing wrapper
How to End War and Disease
Must coordinate adoption at equal or lower cost and failure risk
That is the Minimum Acceptable Governance. The grand prize is for the first mechanism that covers every row or replaces any row with something strictly better.
To put the cost-effectiveness threshold in context:
The full loop: military budgets shrink by 1%, the freed $27.2B/year funds pragmatic trials at 82x lower cost per patient, those trials discover treatments years faster, the treatments save lives and generate economic returns, those returns pay investors who funded the lobbying campaign to pass the treaty, and media coverage of cures creates voter demand that makes expansion easier than repeal. Each stage feeds the next.
The reallocation source. The 1% Treaty150 redirects $27.2B/year by coordinating every signatory to cut the same 1% of military spending simultaneously ($2.72T globally). No new taxes. Proportional reduction preserves relative deterrence. Military spending beyond deterrence returns roughly 0.7:1 on welfare; medical research returns 100:1+.
The medical bottleneck. Current clinical trials cost $41K/patient and exclude 86% of the population, producing a 443 years backlog to clear 6,650 untreated diseases. Pragmatic trials cost $929/patient (the RECOVERY trial found dexamethasone in 3 months for $500/patient and saved 1 million lives86,87). At treaty funding, the queue drops to 36 years. Meanwhile, 102 million people died waiting an average of 8.2 years for drugs already proven to work but stuck in regulatory queues23. Right to Trial eliminates that lag.
The political adoption engine.Incentive Alignment Bonds flip the Olsonian equilibrium: an independent organization scores politicians on net-social-value voting records, PACs support high-scorers, and foundations guarantee post-office careers for champions. Investor returns (272% annually) come from revenue share of treaty-generated funding flows; the benefit-cost ratio is 230138.
The information engine.Optimocracy141 harvests which policies actually improve median income and health across thousands of jurisdictions running natural experiments. The Optimal Policy Generator142 turns that into enact/replace/repeal recommendations. The Optimal Budget Generator149 does the same for spending. The same infrastructure verifies whether the prize’s terminal metrics moved.
Preference aggregation.Wishocracy asks citizens to drag a slider between two random budget priorities. About 20 comparisons, 5 minutes. Statistical models aggregate millions of pairwise judgments into budget-preference weights without speeches, lobbying, or horse-trading. When Optimocracy tells you what works and Wishocracy tells you what people want, the politician’s role shrinks from “decide everything” to “execute or be replaced”147.
None of these mechanisms require inventing new physics. The Montreal Protocol coordinated proportional reduction and worked. PEPFAR saved millions of lives. The RECOVERY trial proved pragmatic trials deliver at 82x lower cost. The open question is not whether these work individually. It is whether combining them, selected and funded via prize, produces better results than deploying them separately or not at all.
How Money Moves
PRIZE tokens fund the prize pool. VOTE tokens allocate it. IABs fund the lobbying campaign. Three instruments, three pools, complementary functions. We have noticed that your species is remarkably good at collecting money for plans and then not building the plans, so the PRIZE pool only distributes when people actually stop dying.
The PRIZE pool is escrowed and distributes when both global targets are met at year 15 (HALE reaches 79 years, median income reaches $504K), proportional to VOTE holdings. Whoever recruited the most coalition gets the most prize money.
The lobbying campaign runs on IAB capital. Bondholders earn a revenue share on success (272% annually), but their incentive to lobby, recruit, and fund implementation work is immediate: every action that raises implementation probability raises bond value today.
Terminal metrics take years to measure, so who funds the implementation work in between? IAB bondholders do, because the work raises their bond value now and the revenue share pays them later. Your species calls this “venture capital” and considers it normal for software companies. It is apparently radical when applied to not dying. Scoring disputes use the same challenge-window mechanism described above.
How It Starts
Abstract mechanism design is harder to trust than a concrete sequence. The three instruments deploy in order, and each stage builds the audience for the next.
Stage 1: PRIZE tokens and the referendum (Months 1-3). PRIZE tokens are the zero-risk on-ramp. Buyers deposit funds into escrow earning 10% (no single keyholder, time-delayed execution so fraud is caught before funds move). If the plan fails, they get their deposit back plus interest. If it succeeds, the pool distributes to VOTE holders. Every PRIZE buyer learns what the prize is for, what the two terminal metrics are, and what the Earth Optimization Plan v1 proposes to do about them. The PRIZE sale IS the awareness campaign. Meanwhile, the referendum platform launches: voters use wishocratic sliders to set their preferred military-to-health allocation, and every recruiter who brings a verified participant earns VOTE tokens. VOTE holders now have a financial stake in the plan succeeding, because their tokens are worth a share of a growing PRIZE pool. They tell people. Those people tell people. The referendum grows because recruitment pays.
Stage 2: Secondary markets and momentum (Months 4-18). VOTE tokens trade on secondary markets. The price is a live signal of what the market thinks recruitment credit is worth, which is a proxy for implementation probability. PRIZE token price signals the pool size and success odds. Two public dashboards, updated by the market, visible to anyone considering whether this is real. Every trade is a news hook. Every price move is a signal to the next tier of participants. The referendum scales to millions. Politicians notice.
Stage 3: IABs and the lobbying campaign (Months 19-36). By now, millions of voters have registered preferences, the PRIZE pool is large enough to be taken seriously, and VOTE token prices signal real momentum. This is when Incentive Alignment Bonds138 launch. IABs are the high-risk, high-return instrument: investor capital funds the lobbying campaign (scorecards, PACs, legislative drafting, treaty advocacy), and on success bondholders earn a pro-rata revenue share at 272% annually. IABs are a harder sell than PRIZE tokens because the capital is genuinely at risk. But by Stage 3, the PRIZE/VOTE ecosystem has already done the hard work: millions of people understand the plan, the referendum headcount is politically meaningful, and the secondary market prices say “this might actually work.” The IAB pitch is not “trust us.” It is “look at the scoreboard.”
Stage 4+: Implementation. The Earth Optimization Plan v1 is submitted as the default reference package: treaty wedge, your decentralized FDA144,145 / continuous evidence generation, regulatory-delay removal, IAB adoption system, Wishocracy preference aggregation, Optimocracy141 / OPG142 / OBG149 recommendation engines, and the statutory path. Bondholders self-organize the lobbying because every action that raises implementation probability raises their bond value. Once one binding path succeeds, budget authority starts shifting real resources. That first success funds the next missing modules until the whole plan is live. Implementers compete inside the winning Earth Optimization Plan v2 to supply the cheapest verified pieces, and later challengers can still replace the whole plan if they genuinely dominate it.
The funnel is: PRIZE tokens create awareness. Awareness creates referendum voters. Voters earn VOTE tokens. VOTE tokens create a financially invested coalition. The coalition makes IABs credible. IABs fund the lobbying campaign. The lobbying campaign passes the treaty. Each stage is the marketing campaign for the next one. Nobody has to coordinate this. The incentives coordinate it.
Why Public Choice Theory Approves
Public choice theory says governments are not run by philosopher-kings. They are run by humans who care about reelection, career advancement, and reputation. This is not a design flaw in humans. It is a design constraint. The prize works with it.
The prize is compatible with public choice because no one has to become good:
Entrepreneurs compete for a giant implementation franchise.
Bondholders recruit voters, lobby politicians, and fund implementation work because all of it raises their bond value.
Investors compete for a share of recovered value.
Politicians compete for campaign support, better scores, reelection odds, and post-office careers.
Bureaucrats compete for control of a better-funded, higher-status program instead of a shrinking one.
Researchers and auditors compete for the authority to validate what works.
Citizens get simpler choices and more visible returns from participation.
Every participant is doing exactly what they would do anyway, except pointed at diseases instead of each other.
Why Contributing Is Rational for You Personally
The arithmetic is simple. If the treaty trajectory is even roughly correct, success raises average lifetime income by $14.9M per person. Any action you take that shifts implementation probability by even a tiny amount is worth real money to you personally:
Increase in implementation probability
Personal expected value (Treaty Trajectory floor, $14.9M)
Personal expected value (Wishonia Trajectory, $52.1M)
Those are not projections about other people’s welfare. They are projections about your income.
If you contribute implementation work (research, software, policy drafting, trial recruitment, coalition building), you can buy IABs and profit from the work raising bond value, or earn VOTE tokens by recruiting and claim a share of the PRIZE pool on success.
The cost of not acting is not zero. Political dysfunction already costs $12.6K per person per year in unrealized value, and the destructive economy is growing faster than the productive one (see Introduction). “Do nothing” is not a neutral baseline. It is a bet that these trends reverse without intervention.
The individual expected value of contributing has four channels:
Channel
What it is
Conservative anchor
You get richer
Per-capita income gain from better resource allocation
The break-even probability shift for any given contribution is small because the per-capita stakes are large:
Your unreimbursed contribution
Break-even probability shift (Treaty floor)
Break-even probability shift (Wishonia)
$1K
0.0067%
0.0019%
$10K
0.067%
0.019%
$100K
0.671%
0.192%
$1M
6.71%
1.92%
But does a $1K contribution actually shift probability by 0.0067%? You do not need to be the marginal dollar that tips the scale. You need to believe that more campaign capital makes success more likely than less, which is nearly tautological for political adoption. But the break-even tables above overstate your risk. They assume your contribution is gone. It is not.
TipThis Is a Free Option, Not a Donation
Contributions come in two flavors. PRIZE tokens are the free option: escrowed at 10% as dominant assurance contracts151, returned at 4.18x if the plan fails. Your actual downside is zero; your money only spends if someone earned it (the VOTE holders who built the coalition). IABs are the investment: your money funds the lobbying campaign, and you earn 272% annual returns from treaty revenue on success.
If the plan succeeds
If the plan fails
$100 PRIZE token
Pool distributes to VOTE holders who built the coalition. Your lifetime income rose by $14.9M like everyone else’s.
272%/year revenue share forever, plus the population-wide income gain
Your money funded the lobbying campaign
The world
Diseases get cured, incomes rise, destructive economy stops compounding
Destructive economy hits 50% of GDP in 15 years; 10% probability of collapse trajectory at year 20
In finance, a position with unlimited upside and zero downside is called a free option. The PRIZE token is one. Your species normally charges a premium for those.
Those thresholds ignore PRIZE token downside protection and IAB revenue share, so they are biased against contributing. They also survive heavy skepticism. If you think the per-capita gain is 100x smaller than modeled ($149K instead of $14.9M), the break-even for a $1K contribution is still only 0.67%. The math does not require trusting the model. It requires believing the model is not off by more than four orders of magnitude. And the ceiling cost of achieving the policy change is already bounded: $1B for the United States, roughly $200B globally, with ROI exceeding 400,000:1 for military-to-health reallocation140.
The free-rider problem has a structural answer. The obvious objection: if success benefits everyone, why not wait and let others pay? Because non-contributors do not get the revenue share. They get the population-wide income gain (everyone does), but they miss the 272% annual return that bondholders collect. Free-riding means giving up the highest-return investment in history to save $100. On your planet this is called “being cheap about the thing that makes you rich.” Early contributors raise the probability of success, which raises the expected value for later contributors, creating a coordination game that runs on arithmetic rather than altruism.
The prize asks one question: who can cause verified implementation of a complete package that wins on welfare per dollar? Contributors allocate wishocratically based on their judgment and Optimitron data141. We wrote v1 because competitions need a starting entry. We expect to lose.
Why This Works or Gets Replaced
There are only two stable outcomes:
The Earth Optimization Plan v1 is mostly right but incomplete. Then whoever augments it with the missing functions and causes implementation receives the prize. The result is the Earth Optimization Plan v2.
A strict improvement exists. Then whoever builds and implements that improvement receives the prize instead (also the Earth Optimization Plan v2), provided it dominates the Minimum Acceptable Governance function by function rather than skipping inconvenient pieces.
Those are the only serious possibilities. The unserious possibility is the one humans choose by default: endless argument with no implementation market. Either way, the prize produces the Earth Optimization Plan v2 and causes its implementation. People are dying at 150 thousand per day while your species argues about mechanism design. Please render v1 obsolete as quickly as possible.
Reward whoever causes the most people to stop dying and start earning more, using any legal method, or replace the current best attempt with a better one.
The mechanism does not need participants to be wise. It needs them to be greedy, impatient, and capable of reading a scoreboard. The remaining variable is how long this takes to become obvious enough to act on.
1.
NIH Common Fund. NIH pragmatic trials: Minimal funding despite 30x cost advantage. NIH Common Fund: HCS Research Collaboratoryhttps://commonfund.nih.gov/hcscollaboratory (2025)
The NIH Pragmatic Trials Collaboratory funds trials at $500K for planning phase, $1M/year for implementation-a tiny fraction of NIH’s budget. The ADAPTABLE trial cost $14 million for 15,076 patients (= $929/patient) versus $420 million for a similar traditional RCT (30x cheaper), yet pragmatic trials remain severely underfunded. PCORnet infrastructure enables real-world trials embedded in healthcare systems, but receives minimal support compared to basic research funding. Additional sources: https://commonfund.nih.gov/hcscollaboratory | https://pcornet.org/wp-content/uploads/2025/08/ADAPTABLE_Lay_Summary_21JUL2025.pdf | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604499/
Mean exclusion rate: 86.1% across 158 antidepressant efficacy trials (range: 44.4% to 99.8%) More than 82% of real-world depression patients would be ineligible for antidepressant registration trials Exclusion rates increased over time: 91.4% (2010-2014) vs. 83.8% (1995-2009) Most common exclusions: comorbid psychiatric disorders, age restrictions, insufficient depression severity, medical conditions Emergency psychiatry patients: only 3.3% eligible (96.7% excluded) when applying 9 common exclusion criteria Only a minority of depressed patients seen in clinical practice are likely to be eligible for most AETs Note: Generalizability of antidepressant trials has decreased over time, with increasingly stringent exclusion criteria eliminating patients who would actually use the drugs in clinical practice Additional sources: https://pubmed.ncbi.nlm.nih.gov/26276679/ | https://pubmed.ncbi.nlm.nih.gov/26164052/ | https://www.wolterskluwer.com/en/news/antidepressant-trials-exclude-most-real-world-patients-with-depression
Berkshire’s compounded annual return from 1965 through 2024 was 19.9%, nearly double the 10.4% recorded by the S&P 500. Berkshire shares skyrocketed 5,502,284% compared to the S&P 500’s 39,054% rise during that period. Additional sources: https://www.cnbc.com/2025/05/05/warren-buffetts-return-tally-after-60-years-5502284percent.html | https://www.slickcharts.com/berkshire-hathaway/returns
Comprehensive mortality and morbidity data by cause, age, sex, country, and year Global mortality: 55-60 million deaths annually Lives saved by modern medicine (vaccines, cardiovascular drugs, oncology): 12M annually (conservative aggregate) Leading causes of death: Cardiovascular disease (17.9M), Cancer (10.3M), Respiratory disease (4.0M) Note: Baseline data for regulatory mortality analysis. Conservative estimate of pharmaceutical impact based on WHO immunization data (4.5M/year from vaccines) + cardiovascular interventions (3.3M/year) + oncology (1.5M/year) + other therapies. Additional sources: https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates
General range: $3,000-$5,500 per life saved (GiveWell top charities) Helen Keller International (Vitamin A): $3,500 average (2022-2024); varies $1,000-$8,500 by country Against Malaria Foundation: $5,500 per life saved New Incentives (vaccination incentives): $4,500 per life saved Malaria Consortium (seasonal malaria chemoprevention): $3,500 per life saved VAS program details: $2 to provide vitamin A supplements to child for one year Note: Figures accurate for 2024. Helen Keller VAS program has wide country variation ($1K-$8.5K) but $3,500 is accurate average. Among most cost-effective interventions globally Additional sources: https://www.givewell.org/charities/top-charities | https://www.givewell.org/charities/helen-keller-international | https://ourworldindata.org/cost-effectiveness
Average family caregiver: 25-26 hours per week (100-104 hours per month) 38 million caregivers providing 36 billion hours of care annually Economic value: $16.59 per hour = $600 billion total annual value (2021) 28% of people provided eldercare on a given day, averaging 3.9 hours when providing care Caregivers living with care recipient: 37.4 hours per week Caregivers not living with recipient: 23.7 hours per week Note: Disease-related caregiving is subset of total; includes elderly care, disability care, and child care Additional sources: https://www.aarp.org/caregiving/financial-legal/info-2023/unpaid-caregivers-provide-billions-in-care.html | https://www.bls.gov/news.release/elcare.nr0.htm | https://www.caregiver.org/resource/caregiver-statistics-demographics/
Forbes identified a record 2,781 billionaires worldwide with combined net worth of $14.2 trillion, 141 more than 2023. Bernard Arnault (LVMH) topped the list at $233 billion.
US programs (1994-2023): $540B direct savings, $2.7T societal savings ( $18B/year direct, $90B/year societal) Global (2001-2020): $820B value for 10 diseases in 73 countries ( $41B/year) ROI: $11 return per $1 invested Measles vaccination alone saved 93.7M lives (61% of 154M total) over 50 years (1974-2024) Additional sources: https://www.cdc.gov/mmwr/volumes/73/wr/mm7331a2.htm | https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00850-X/fulltext
CPI-U (1980): 82.4 CPI-U (2024): 313.5 Inflation multiplier (1980-2024): 3.80× Cumulative inflation: 280.48% Average annual inflation rate: 3.08% Note: Official U.S. government inflation data using Consumer Price Index for All Urban Consumers (CPI-U). Additional sources: https://www.bls.gov/data/inflation_calculator.htm
.
11.
ClinicalTrials.gov API v2 direct analysis. ClinicalTrials.gov cumulative enrollment data (2025). Direct analysis via ClinicalTrials.gov API v2https://clinicaltrials.gov/data-api/api
Analysis of 100,000 active/recruiting/completed trials on ClinicalTrials.gov (as of January 2025) shows cumulative enrollment of 12.2 million participants: Phase 1 (722k), Phase 2 (2.2M), Phase 3 (6.5M), Phase 4 (2.7M). Median participants per trial: Phase 1 (33), Phase 2 (60), Phase 3 (237), Phase 4 (90). Additional sources: https://clinicaltrials.gov/data-api/api
Only 3-5% of adult cancer patients in US receive treatment within clinical trials About 5% of American adults have ever participated in any clinical trial Oncology: 2-3% of all oncology patients participate Contrast: 50-60% enrollment for pediatric cancer trials (<15 years old) Note: 20% of cancer trials fail due to insufficient enrollment; 11% of research sites enroll zero patients Additional sources: https://www.fightcancer.org/policy-resources/barriers-patient-enrollment-therapeutic-clinical-trials-cancer | https://hints.cancer.gov/docs/Briefs/HINTS_Brief_48.pdf
2.3 billion individuals had more than five ailments (2013) Chronic conditions caused 74% of all deaths worldwide (2019), up from 67% (2010) Approximately 1 in 3 adults suffer from multiple chronic conditions (MCCs) Risk factor exposures: 2B exposed to biomass fuel, 1B to air pollution, 1B smokers Projected economic cost: $47 trillion by 2030 Note: 2.3B with 5+ ailments is more accurate than "2B with chronic disease." One-third of all adults globally have multiple chronic conditions Additional sources: https://www.sciencedaily.com/releases/2015/06/150608081753.htm | https://pmc.ncbi.nlm.nih.gov/articles/PMC10830426/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC6214883/
Approximately 12% of trials with results posted on the ClinicalTrials.gov results database (905/7,646) were terminated. Primary reasons: insufficient accrual (57% of non-data-driven terminations), business/strategic reasons, and efficacy/toxicity findings (21% data-driven terminations).
Global clinical trials market valued at approximately $83 billion in 2024, with projections to reach $83-132 billion by 2030. Additional sources: https://www.globenewswire.com/news-release/2024/04/19/2866012/0/en/Global-Clinical-Trials-Market-Research-Report-2024-An-83-16-Billion-Market-by-2030-AI-Machine-Learning-and-Blockchain-will-Transform-the-Clinical-Trials-Landscape.html | https://www.precedenceresearch.com/clinical-trials-market
Schistosomiasis treatment: $28.19-$70.48 per DALY (using arithmetic means with varying disability weights) Soil-transmitted helminths (STH) treatment: $82.54 per DALY (midpoint estimate) Note: GiveWell explicitly states this 2011 analysis is "out of date" and their current methodology focuses on long-term income effects rather than short-term health DALYs Additional sources: https://www.givewell.org/international/technical/programs/deworming/cost-effectiveness
.
20.
Calculated from IHME Global Burden of Disease (2.55B DALYs) and global GDP per capita valuation. $109 trillion annual global disease burden.
The global economic burden of disease, including direct healthcare costs ($8.2 trillion) and lost productivity ($100.9 trillion from 2.55 billion DALYs × $39,570 per DALY), totals approximately $109.1 trillion annually.
Phase I duration: 2.3 years average Total time to market (Phase I-III + approval): 10.5 years average Phase transition success rates: Phase I→II: 63.2%, Phase II→III: 30.7%, Phase III→Approval: 58.1% Overall probability of approval from Phase I: 12% Note: Largest publicly available study of clinical trial success rates. Efficacy lag = 10.5 - 2.3 = 8.2 years post-safety verification. Additional sources: https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf
Approximately 30% of drugs gain at least one new indication after initial approval. Additional sources: https://www.nature.com/articles/s41591-024-03233-x
Early childhood education: Benefits 12X outlays by 2050; $8.70 per dollar over lifetime Educational facilities: $1 spent → $1.50 economic returns Energy efficiency comparison: 2-to-1 benefit-to-cost ratio (McKinsey) Private return to schooling: 9% per additional year (World Bank meta-analysis) Note: 2.1 multiplier aligns with benefit-to-cost ratios for educational infrastructure/energy efficiency. Early childhood education shows much higher returns (12X by 2050) Additional sources: https://www.epi.org/publication/bp348-public-investments-outside-core-infrastructure/ | https://documents1.worldbank.org/curated/en/442521523465644318/pdf/WPS8402.pdf | https://freopp.org/whitepapers/establishing-a-practical-return-on-investment-framework-for-education-and-skills-development-to-expand-economic-opportunity/
Infrastructure fiscal multiplier: 1.6 during contractionary phase of economic cycle Average across all economic states: 1.5 (meaning $1 of public investment → $1.50 of economic activity) Time horizon: 0.8 within 1 year, 1.5 within 2-5 years Range of estimates: 1.5-2.0 (following 2008 financial crisis & American Recovery Act) Italian public construction: 1.5-1.9 multiplier US ARRA: 0.4-2.2 range (differential impacts by program type) Economic Policy Institute: Uses 1.6 for infrastructure spending (middle range of estimates) Note: Public investment less likely to crowd out private activity during recessions; particularly effective when monetary policy loose with near-zero rates Additional sources: https://blogs.worldbank.org/en/ppps/effectiveness-infrastructure-investment-fiscal-stimulus-what-weve-learned | https://www.gihub.org/infrastructure-monitor/insights/fiscal-multiplier-effect-of-infrastructure-investment/ | https://cepr.org/voxeu/columns/government-investment-and-fiscal-stimulus | https://www.richmondfed.org/publications/research/economic_brief/2022/eb_22-04
Ramey (2011): 0.6 short-run multiplier Barro (1981): 0.6 multiplier for WWII spending (war spending crowded out 40¢ private economic activity per federal dollar) Barro & Redlick (2011): 0.4 within current year, 0.6 over two years; increased govt spending reduces private-sector GDP portions General finding: $1 increase in deficit-financed federal military spending = less than $1 increase in GDP Variation by context: Central/Eastern European NATO: 0.6 on impact, 1.5-1.6 in years 2-3, gradual fall to zero Ramey & Zubairy (2018): Cumulative 1% GDP increase in military expenditure raises GDP by 0.7% Additional sources: https://www.mercatus.org/research/research-papers/defense-spending-and-economy | https://cepr.org/voxeu/columns/world-war-ii-america-spending-deficits-multipliers-and-sacrifice | https://www.rand.org/content/dam/rand/pubs/research_reports/RRA700/RRA739-2/RAND_RRA739-2.pdf
The FDA GRAS (Generally Recognized as Safe) list contains approximately 570–700 substances. Additional sources: https://www.fda.gov/food/generally-recognized-safe-gras/gras-notice-inventory
2024: 233,597 deaths (30% increase from 179,099 in 2023) Deadliest conflicts: Ukraine (67,000), Palestine (35,000) Nearly 200,000 acts of violence (25% higher than 2023, double from 5 years ago) One in six people globally live in conflict-affected areas Additional sources: https://acleddata.com/2024/12/12/data-shows-global-conflict-surged-in-2024-the-washington-post/ | https://acleddata.com/media-citation/data-shows-global-conflict-surged-2024-washington-post | https://acleddata.com/conflict-index/index-january-2024/
.
32.
UCDP. State violence deaths annually. UCDP: Uppsala Conflict Data Programhttps://ucdp.uu.se/
Uppsala Conflict Data Program (UCDP): Tracks one-sided violence (organized actors attacking unarmed civilians) UCDP definition: Conflicts causing at least 25 battle-related deaths in calendar year 2023 total organized violence: 154,000 deaths; Non-state conflicts: 20,900 deaths UCDP collects data on state-based conflicts, non-state conflicts, and one-sided violence Specific "2,700 annually" figure for state violence not found in recent UCDP data; actual figures vary annually Additional sources: https://ucdp.uu.se/ | https://en.wikipedia.org/wiki/Uppsala_Conflict_Data_Program | https://ourworldindata.org/grapher/deaths-in-armed-conflicts-by-region
2023: 8,352 deaths (22% increase from 2022, highest since 2017) 2023: 3,350 terrorist incidents (22% decrease), but 56% increase in avg deaths per attack Global Terrorism Database (GTD): 200,000+ terrorist attacks recorded (2021 version) Maintained by: National Consortium for Study of Terrorism & Responses to Terrorism (START), U. of Maryland Geographic shift: Epicenter moved from Middle East to Central Sahel (sub-Saharan Africa) - now >50% of all deaths Additional sources: https://ourworldindata.org/terrorism | https://reliefweb.int/report/world/global-terrorism-index-2024 | https://www.start.umd.edu/gtd/ | https://ourworldindata.org/grapher/fatalities-from-terrorism
.
34.
Institute for Health Metrics and Evaluation (IHME). IHME global burden of disease 2021 (2.88B DALYs, 1.13B YLD). Institute for Health Metrics and Evaluation (IHME)https://vizhub.healthdata.org/gbd-results/ (2024)
In 2021, global DALYs totaled approximately 2.88 billion, comprising 1.75 billion Years of Life Lost (YLL) and 1.13 billion Years Lived with Disability (YLD). This represents a 13% increase from 2019 (2.55B DALYs), largely attributable to COVID-19 deaths and aging populations. YLD accounts for approximately 39% of total DALYs, reflecting the substantial burden of non-fatal chronic conditions. Additional sources: https://vizhub.healthdata.org/gbd-results/ | https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00757-8/fulltext | https://www.healthdata.org/research-analysis/about-gbd
War on Terror emissions: 1.2B metric tons GHG (equivalent to 257M cars/year) Military: 5.5% of global GHG emissions (2X aviation + shipping combined) US DoD: World’s single largest institutional oil consumer, 47th largest emitter if nation Cleanup costs: $500B+ for military contaminated sites Gaza war environmental damage: $56.4B; landmine clearance: $34.6B expected Climate finance gap: Rich nations spend 30X more on military than climate finance Note: Military activities cause massive environmental damage through GHG emissions, toxic contamination, and long-term cleanup costs far exceeding current climate finance commitments Additional sources: https://watson.brown.edu/costsofwar/costs/social/environment | https://earth.org/environmental-costs-of-wars/ | https://transformdefence.org/transformdefence/stats/
Global military spending: $2.7 trillion (2024, SIPRI) Global government medical research: $68 billion (2024) Actual ratio: 39.7:1 in favor of weapons over medical research Military R&D alone: $85B (2004 data, 10% of global R&D) Military spending increases crowd out health: 1% ↑ military = 0.62% ↓ health spending Note: Ratio actually worse than 36:1. Each 1% increase in military spending reduces health spending by 0.62%, with effect more intense in poorer countries (0.962% reduction) Additional sources: https://www.sipri.org/commentary/blog/2016/opportunity-cost-world-military-spending | https://pmc.ncbi.nlm.nih.gov/articles/PMC9174441/ | https://www.congress.gov/crs-product/R45403
Lost human capital from war: $300B annually (economic impact of losing skilled/productive individuals to conflict) Broader conflict/violence cost: $14T/year globally 1.4M violent deaths/year; conflict holds back economic development, causes instability, widens inequality, erodes human capital 2002: 48.4M DALYs lost from 1.6M violence deaths = $151B economic value (2000 USD) Economic toll includes: commodity prices, inflation, supply chain disruption, declining output, lost human capital Additional sources: https://thinkbynumbers.org/military/war/the-economic-case-for-peace-a-comprehensive-financial-analysis/ | https://www.weforum.org/stories/2021/02/war-violence-costs-each-human-5-a-day/ | https://pubmed.ncbi.nlm.nih.gov/19115548/
PTSD economic burden (2018 U.S.): $232.2B total ($189.5B civilian, $42.7B military) Civilian costs driven by: Direct healthcare ($66B), unemployment ($42.7B) Military costs driven by: Disability ($17.8B), direct healthcare ($10.1B) Exceeds costs of other mental health conditions (anxiety, depression) War-exposed populations: 2-3X higher rates of anxiety, depression, PTSD; women and children most vulnerable Note: Actual burden $232B, significantly higher than "$100B" claimed Additional sources: https://pubmed.ncbi.nlm.nih.gov/35485933/ | https://news.va.gov/103611/study-national-economic-burden-of-ptsd-staggering/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9957523/
The average cost of supporting a refugee is $1,384 per year. This represents total host country costs (housing, healthcare, education, security). OECD countries average $6,100 per refugee (mean 2022-2023), with developing countries spending $700-1,000. Global weighted average of $1,384 is reasonable given that 75-85% of refugees are in low/middle-income countries. Additional sources: https://www.cgdev.org/blog/costs-hosting-refugees-oecd-countries-and-why-uk-outlier | https://www.unhcr.org/sites/default/files/2024-11/UNHCR-WB-global-cost-of-refugee-inclusion-in-host-country-health-systems.pdf
Estimated $616B annual cost from conflict-related trade disruption. World Bank research shows civil war costs an average developing country 30 years of GDP growth, with 20 years needed for trade to return to pre-war levels. Trade disputes analysis shows tariff escalation could reduce global exports by up to $674 billion. Additional sources: https://www.worldbank.org/en/topic/trade/publication/trading-away-from-conflict | https://www.nber.org/papers/w11565 | http://blogs.worldbank.org/en/trade/impacts-global-trade-and-income-current-trade-disputes
Global days of therapy reached 1.8 trillion in 2019 (234 defined daily doses per person). Diabetes, respiratory, CVD, and cancer account for 71 percent of medicine use. Projected to reach 3.8 trillion DDDs by 2028.
Estimated private pharmaceutical and biotech clinical trial spending is approximately $75-90 billion annually, representing roughly 90% of global clinical trial spending.
Global cybercrime costs: $3T (2015) → $6T (2021) → $10.5T (2025 projected) 15% annual growth rate If measured as country, would be 3rd largest economy after US and China Greatest transfer of economic wealth in history Note: More profitable than global trade of all major illegal drugs combined. Includes data theft, productivity loss, IP theft, fraud Additional sources: <https://cybersecurityventures.com/hackerpocalypse-cybercrime-report-2016/> | https://www.boisestate.edu/cybersecurity/2022/06/16/cybercrime-to-cost-the-world-10-5-trillion-annually-by-2025/
Quantifying the gap between current global governance and theoretical maximum welfare, estimating a 31-53% efficiency score and $97 trillion in annual opportunity costs.
Estimated range based on NIH ( $0.8-5.6B), NIHR ($1.6B total budget), and EU funding ( $1.3B/year). Roughly 5-10% of global market. Additional sources: https://www.appliedclinicaltrialsonline.com/view/sizing-clinical-research-market | https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(20)30357-0/fulltext
Total global household wealth: USD 454.4 trillion (2022) Wealth declined by USD 11.3 trillion (-2.4%) in 2022, first decline since 2008 Wealth per adult: USD 84,718 Additional sources: https://www.ubs.com/global/en/family-office-uhnw/reports/global-wealth-report-2023.html
The 2024 Revision of the World Population Prospects provides population estimates and projections for 237 countries or areas. Global median age approximately 30.5 years in 2024, reflecting population-weighted average across all regions.
Estimated from major foundation budgets and activities. Nonprofit clinical trial funding estimate.
Nonprofit foundations spend an estimated $2-5 billion annually on clinical trials globally, representing approximately 2-5% of total clinical trial spending.
54.
Industry reports: IQVIA. Global pharmaceutical r&d spending.
Total global pharmaceutical R&D spending is approximately $300 billion annually. Clinical trials represent 15-20% of this total ($45-60B), with the remainder going to drug discovery, preclinical research, regulatory affairs, and manufacturing development.
Milestone: November 15, 2022 (UN World Population Prospects 2022) Day of Eight Billion" designated by UN Added 1 billion people in just 11 years (2011-2022) Growth rate: Slowest since 1950; fell under 1% in 2020 Future: 15 years to reach 9B (2037); projected peak 10.4B in 2080s Projections: 8.5B (2030), 9.7B (2050), 10.4B (2080-2100 plateau) Note: Milestone reached Nov 2022. Population growth slowing; will take longer to add next billion (15 years vs 11 years) Additional sources: https://www.un.org/en/desa/world-population-reach-8-billion-15-november-2022 | https://www.un.org/en/dayof8billion | https://en.wikipedia.org/wiki/Day_of_Eight_Billion
The research found that nonviolent campaigns were twice as likely to succeed as violent ones, and once 3.5% of the population were involved, they were always successful. Chenoweth and Maria Stephan studied the success rates of civil resistance efforts from 1900 to 2006, finding that nonviolent movements attracted, on average, four times as many participants as violent movements and were more likely to succeed. Key finding: Every campaign that mobilized at least 3.5% of the population in sustained protest was successful (in their 1900-2006 dataset) Note: The 3.5% figure is a descriptive statistic from historical analysis, not a guaranteed threshold. One exception (Bahrain 2011-2014 with 6%+ participation) has been identified. The rule applies to regime change, not policy change in democracies. Additional sources: https://www.hks.harvard.edu/centers/carr/publications/35-rule-how-small-minority-can-change-world | https://www.hks.harvard.edu/sites/default/files/2024-05/Erica%20Chenoweth_2020-005.pdf | https://www.bbc.com/future/article/20190513-it-only-takes-35-of-people-to-change-the-world | https://en.wikipedia.org/wiki/3.5%25_rule
Your DNA is 3 billion base pairs Read the entire code (Human Genome Project, completed 2003) Learned to edit it (CRISPR, discovered 2012) Additional sources: https://www.genome.gov/11006929/2003-release-international-consortium-completes-hgp | https://www.nobelprize.org/prizes/chemistry/2020/press-release/
Mapping 350,000+ clinical trials showed that only 12% of the human interactome has ever been targeted by drugs. Additional sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC10749231/
The ICD-10 classification contains approximately 14,000 codes for diseases, signs and symptoms. Additional sources: https://icd.who.int/browse10/2019/en
Longevity escape velocity: Hypothetical point where medical advances extend life expectancy faster than time passes Term coined by Aubrey de Grey (biogerontologist) in 2004 paper; concept from David Gobel (Methuselah Foundation) Current progress: Science adds 3 months to lifespan per year; LEV requires adding >1 year per year Sinclair (Harvard): "There is no biological upper limit to age" - first person to live to 150 may already be born De Grey: 50% chance of reaching LEV by mid-to-late 2030s; SENS approach = damage repair rather than slowing damage Kurzweil (2024): LEV by 2029-2035, AI will simulate biological processes to accelerate solutions George Church: LEV "in a decade or two" via age-reversal clinical trials Natural lifespan cap: 120-150 years (Jeanne Calment record: 122); engineering approach could bypass via damage repair Key mechanisms: Epigenetic reprogramming, senolytic drugs, stem cell therapy, gene therapy, AI-driven drug discovery Current record: Jeanne Calment (122 years, 164 days) - record unbroken since 1997 Note: LEV is theoretical but increasingly plausible given demonstrated age reversal in mice (109% lifespan extension) and human cells (30-year epigenetic age reversal) Additional sources: https://en.wikipedia.org/wiki/Longevity_escape_velocity | https://pmc.ncbi.nlm.nih.gov/articles/PMC423155/ | https://www.popularmechanics.com/science/a36712084/can-science-cure-death-longevity/ | https://www.diamandis.com/blog/longevity-escape-velocity
Registered lobbyists: Over 12,000 (some estimates); 12,281 registered (2013) Former government employees as lobbyists: 2,200+ former federal employees (1998-2004), including 273 former White House staffers, 250 former Congress members & agency heads Congressional revolving door: 43% (86 of 198) lawmakers who left 1998-2004 became lobbyists; currently 59% leaving to private sector work for lobbying/consulting firms/trade groups Executive branch: 8% were registered lobbyists at some point before/after government service Additional sources: https://en.wikipedia.org/wiki/Lobbying_in_the_United_States | https://www.opensecrets.org/revolving-door | https://www.citizen.org/article/revolving-congress/ | https://www.propublica.org/article/we-found-a-staggering-281-lobbyists-whove-worked-in-the-trump-administration
Single measles vaccination: 167:1 benefit-cost ratio. MMR (measles-mumps-rubella) vaccination: 14:1 ROI. Historical US elimination efforts (1966-1974): benefit-cost ratio of 10.3:1 with net benefits exceeding USD 1.1 billion (1972 dollars, or USD 8.0 billion in 2023 dollars). 2-dose MMR programs show direct benefit/cost ratio of 14.2 with net savings of $5.3 billion, and 26.0 from societal perspectives with net savings of $11.6 billion. Additional sources: https://www.mdpi.com/2076-393X/12/11/1210 | https://www.tandfonline.com/doi/full/10.1080/14760584.2024.2367451
One in four people in the world will be affected by mental or neurological disorders at some point in their lives, representing [approximately] 30% of the global burden of disease. Additional sources: https://www.who.int/news/item/28-09-2001-the-world-health-report-2001-mental-disorders-affect-one-in-four-people
Under the current system, approximately 10-15 diseases per year receive their FIRST effective treatment. Calculation: 5% of 7,000 rare diseases ( 350) have FDA-approved treatment, accumulated over 40 years of the Orphan Drug Act = 9 rare diseases/year. Adding 5-10 non-rare diseases that get first treatments yields 10-20 total. FDA approves 50 drugs/year, but many are for diseases that already have treatments (me-too drugs, second-line therapies). Only 15 represent truly FIRST treatments for previously untreatable conditions.
The budget total of $47.7 billion also includes $1.412 billion derived from PHS Evaluation financing... Additional sources: https://www.nih.gov/about-nih/organization/budget | https://officeofbudget.od.nih.gov/
Typical cost-effectiveness thresholds for medical interventions in rich countries range from $50,000 to $150,000 per QALY. The Institute for Clinical and Economic Review (ICER) uses a $100,000-$150,000/QALY threshold for value-based pricing. Between 1990-2021, authors increasingly cited $100,000 (47% by 2020-21) or $150,000 (24% by 2020-21) per QALY as benchmarks for cost-effectiveness. Additional sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC10114019/ | https://icer.org/our-approach/methods-process/cost-effectiveness-the-qaly-and-the-evlyg/
Recent surveys: 49-51% willingness (2020-2022) - dramatic drop from 85% (2019) during COVID-19 pandemic Cancer patients when approached: 88% consented to trials (Royal Marsden Hospital) Study type variation: 44.8% willing for drug trial, 76.2% for diagnostic study Top motivation: "Learning more about my health/medical condition" (67.4%) Top barrier: "Worry about experiencing side effects" (52.6%) Additional sources: https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-015-1105-3 | https://www.appliedclinicaltrialsonline.com/view/industry-forced-to-rethink-patient-participation-in-trials | https://pmc.ncbi.nlm.nih.gov/articles/PMC7183682/
.
72.
Tufts CSDD. Cost of drug development.
Various estimates suggest $1.0 - $2.5 billion to bring a new drug from discovery through FDA approval, spread across 10 years. Tufts Center for the Study of Drug Development often cited for $1.0 - $2.6 billion/drug. Industry reports (IQVIA, Deloitte) also highlight $2+ billion figures.
Study of 361 FDA-approved drugs from 1995-2014 (median follow-up 13.2 years): Mean lifetime revenue: $15.2 billion per drug Median lifetime revenue: $6.7 billion per drug Revenue after 5 years: $3.2 billion (mean) Revenue after 10 years: $9.5 billion (mean) Revenue after 15 years: $19.2 billion (mean) Distribution highly skewed: top 25 drugs (7%) accounted for 38% of total revenue ($2.1T of $5.5T) Additional sources: https://www.sciencedirect.com/science/article/pii/S1098301524027542
Using 3-way fixed-effects methodology (disease-country-year) across 66 diseases in 22 countries, this study estimates that drugs launched after 1981 saved 148.7 million life-years in 2013 alone. The regression coefficients for drug launches 0-11 years prior (beta=-0.031, SE=0.008) and 12+ years prior (beta=-0.057, SE=0.013) on years of life lost are highly significant (p<0.0001). Confidence interval for life-years saved: 79.4M-239.8M (95 percent CI) based on propagated standard errors from Table 2.
Deloitte’s annual study of top 20 pharma companies by R&D spend (2010-2024): 2024 ROI: 5.9% (second year of growth after decade of decline) 2023 ROI: 4.3% (estimated from trend) 2022 ROI: 1.2% (historic low since study began, 13-year low) 2021 ROI: 6.8% (record high, inflated by COVID-19 vaccines/treatments) Long-term trend: Declining for over a decade before 2023 recovery Average R&D cost per asset: $2.3B (2022), $2.23B (2024) These returns (1.2-5.9% range) fall far below typical corporate ROI targets (15-20%) Additional sources: https://www.deloitte.com/ch/en/Industries/life-sciences-health-care/research/measuring-return-from-pharmaceutical-innovation.html | https://www.prnewswire.com/news-releases/deloittes-13th-annual-pharmaceutical-innovation-report-pharma-rd-return-on-investment-falls-in-post-pandemic-market-301738807.html | https://hitconsultant.net/2023/02/16/pharma-rd-roi-falls-to-lowest-level-in-13-years/
.
76.
Nature Reviews Drug Discovery. Drug trial success rate from phase i to approval. Nature Reviews Drug Discovery: Clinical Success Rateshttps://www.nature.com/articles/nrd.2016.136 (2016)
Overall Phase I to approval: 10-12.8% (conventional wisdom 10%, studies show 12.8%) Recent decline: Average LOA now 6.7% for Phase I (2014-2023 data) Leading pharma companies: 14.3% average LOA (range 8-23%) Varies by therapeutic area: Oncology 3.4%, CNS/cardiovascular lowest at Phase III Phase-specific success: Phase I 47-54%, Phase II 28-34%, Phase III 55-70% Note: 12% figure accurate for historical average. Recent data shows decline to 6.7%, with Phase II as primary attrition point (28% success) Additional sources: https://www.nature.com/articles/nrd.2016.136 | https://pmc.ncbi.nlm.nih.gov/articles/PMC6409418/ | https://academic.oup.com/biostatistics/article/20/2/273/4817524
Phase 3 clinical trials cost between $20 million and $282 million per trial, with significant variation by therapeutic area and trial complexity. Additional sources: https://www.sofpromed.com/how-much-does-a-clinical-trial-cost | https://www.cbo.gov/publication/57126
Meta-analysis of 108 embedded pragmatic clinical trials (2006-2016). The median cost per patient was $97 (IQR $19–$478), based on 2015 dollars. 25% of trials cost <$19/patient; 10 trials exceeded $1,000/patient. U.S. studies median $187 vs non-U.S. median $27. Additional sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC6508852/
For every dollar spent, the return on investment is nearly US$ 39." Total investment cost of US$ 7.5 billion generates projected economic and social benefits of US$ 289.2 billion from sustaining polio assets and integrating them into expanded immunization, surveillance and emergency response programmes across 8 priority countries (Afghanistan, Iraq, Libya, Pakistan, Somalia, Sudan, Syria, Yemen). Additional sources: https://www.who.int/news-room/feature-stories/detail/sustaining-polio-investments-offers-a-high-return
ICBL: Founded 1992 by 6 NGOs (Handicap International, Human Rights Watch, Medico International, Mines Advisory Group, Physicians for Human Rights, Vietnam Veterans of America Foundation) Started with ONE staff member: Jody Williams as founding coordinator Grew to 1,000+ organizations in 60 countries by 1997 Ottawa Process: 14 months (October 1996 - December 1997) Convention signed by 122 states on December 3, 1997; entered into force March 1, 1999 Achievement: Nobel Peace Prize 1997 (shared by ICBL and Jody Williams) Government funding context: Canada established $100M CAD Canadian Landmine Fund over 10 years (1997); International donors provided $169M in 1997 for mine action (up from $100M in 1996) Additional sources: https://www.icrc.org/en/doc/resources/documents/article/other/57jpjn.htm | https://en.wikipedia.org/wiki/International_Campaign_to_Ban_Landmines | https://www.nobelprize.org/prizes/peace/1997/summary/ | https://un.org/press/en/1999/19990520.MINES.BRF.html | https://www.the-monitor.org/en-gb/reports/2003/landmine-monitor-2003/mine-action-funding.aspx
388 former members of Congress are registered as lobbyists. Nearly 5,400 former congressional staffers have left Capitol Hill to become federal lobbyists in the past 10 years. Additional sources: https://www.opensecrets.org/revolving-door
Research identified 1,600+ medicines available in 1962. The 1950s represented industry high-water mark with >30 new products in five of ten years; this rate would not be replicated until late 1990s. More than half (880) of these medicines were lost following implementation of Kefauver-Harris Amendment. The peak of 1962 would not be seen again until early 21st century. By 2016 number of organizations actively involved in R&D at level not seen since 1914.
Pre-1962: Average cost per new chemical entity (NCE) was $6.5 million (1980 dollars) Inflation-adjusted to 2024 dollars: $6.5M (1980) ≈ $22.5M (2024), using CPI multiplier of 3.46× Real cost increase (inflation-adjusted): $22.5M (pre-1962) → $2,600M (2024) = 116× increase Note: This represents the most comprehensive academic estimate of pre-1962 drug development costs based on empirical industry data Additional sources: https://samizdathealth.org/wp-content/uploads/2020/12/hlthaff.1.2.6.pdf
Pre-1962: Physicians could report real-world evidence directly 1962 Drug Amendments replaced "premarket notification" with "premarket approval", requiring extensive efficacy testing Impact: New regulatory clampdown reduced new treatment production by 70%; lifespan growth declined from 4 years/decade to 2 years/decade Drug Efficacy Study Implementation (DESI): NAS/NRC evaluated 3,400+ drugs approved 1938-1962 for safety only; reviewed >3,000 products, >16,000 therapeutic claims FDA has had authority to accept real-world evidence since 1962, clarified by 21st Century Cures Act (2016) Note: Specific "144,000 physicians" figure not verified in sources Additional sources: https://thinkbynumbers.org/health/how-many-net-lives-does-the-fda-save/ | https://www.fda.gov/drugs/enforcement-activities-fda/drug-efficacy-study-implementation-desi | http://www.nasonline.org/about-nas/history/archives/collections/des-1966-1969-1.html
The RECOVERY trial, for example, cost only about $500 per patient... By contrast, the median per-patient cost of a pivotal trial for a new therapeutic is around $41,000. Additional sources: https://manhattan.institute/article/slow-costly-clinical-trials-drag-down-biomedical-breakthroughs
Dexamethasone saved 1 million lives worldwide (NHS England estimate, March 2021, 9 months after discovery). UK alone: 22,000 lives saved. Methodology: Águas et al. Nature Communications 2021 estimated 650,000 lives (range: 240,000-1,400,000) for July-December 2020 alone, based on RECOVERY trial mortality reductions (36% for ventilated, 18% for oxygen-only patients) applied to global COVID hospitalizations. June 2020 announcement: Dexamethasone reduced deaths by up to 1/3 (ventilated patients), 1/5 (oxygen patients). Impact immediate: Adopted into standard care globally within hours of announcement. Additional sources: https://www.england.nhs.uk/2021/03/covid-treatment-developed-in-the-nhs-saves-a-million-lives/ | https://www.nature.com/articles/s41467-021-21134-2 | https://pharmaceutical-journal.com/article/news/steroid-has-saved-the-lives-of-one-million-covid-19-patients-worldwide-figures-show | https://www.recoverytrial.net/news/recovery-trial-celebrates-two-year-anniversary-of-life-saving-dexamethasone-result
2,977 people were killed in the September 11, 2001 attacks: 2,753 at the World Trade Center, 184 at the Pentagon, and 40 passengers and crew on United Flight 93 in Shanksville, Pennsylvania.
Singapore GDP per capita (2023): $82,000 - among highest in the world Government spending: 15% of GDP (vs US 38%) Life expectancy: 84.1 years (vs US 77.5 years) Singapore demonstrates that low government spending can coexist with excellent outcomes Additional sources: https://data.worldbank.org/country/singapore
Singapore government spending is approximately 15% of GDP This is 23 percentage points lower than the United States (38%) Despite lower spending, Singapore achieves excellent outcomes: - Life expectancy: 84.1 years (vs US 77.5) - Low crime, world-class infrastructure, AAA credit rating Additional sources: https://www.imf.org/en/Countries/SGP
Life expectancy at birth varies significantly among developed nations: Switzerland: 84.0 years (2023) Singapore: 84.1 years (2023) Japan: 84.3 years (2023) United States: 77.5 years (2023) - 6.5 years below Switzerland, Singapore Global average: 73 years Note: US spends more per capita on healthcare than any other nation, yet achieves lower life expectancy Additional sources: https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-life-expectancy-and-healthy-life-expectancy
Population-level: Up to 14% (9% men, 14% women) of total life expectancy gain since 1960 due to tobacco control efforts Individual cessation benefits: Quitting at age 35 adds 6.9-8.5 years (men), 6.1-7.7 years (women) vs continuing smokers By cessation age: Age 25-34 = 10 years gained; age 35-44 = 9 years; age 45-54 = 6 years; age 65 = 2.0 years (men), 3.7 years (women) Cessation before age 40: Reduces death risk by 90% Long-term cessation: 10+ years yields survival comparable to never smokers, averts 10 years of life lost Recent cessation: <3 years averts 5 years of life lost Additional sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1447499/ | https://www.cdc.gov/pcd/issues/2012/11_0295.htm | https://www.ajpmonline.org/article/S0749-3797(24)00217-4/fulltext | https://www.nejm.org/doi/full/10.1056/NEJMsa1211128
Standard economic value per QALY: $100,000–$150,000. This is the US and global standard willingness-to-pay threshold for interventions that add costs. Dominant interventions (those that save money while improving health) are favorable regardless of this threshold. Additional sources: https://icer.org/wp-content/uploads/2024/02/Reference-Case-4.3.25.pdf
Consumer costs: $2.5-3.5 billion per year (GAO estimate) Net economic cost: $1 billion per year 2022: US consumers paid 2X world price for sugar Program costs $3-4 billion/year but no federal budget impact (costs passed directly to consumers via higher prices) Employment impact: 10,000-20,000 manufacturing jobs lost annually in sugar-reliant industries (confectionery, etc.) Multiple studies confirm: Sweetener Users Association ($2.9-3.5B), AEI ($2.4B consumer cost), Beghin & Elobeid ($2.9-3.5B consumer surplus) Additional sources: https://www.gao.gov/products/gao-24-106144 | https://www.heritage.org/agriculture/report/the-us-sugar-program-bad-consumers-bad-agriculture-and-bad-america | https://www.aei.org/articles/the-u-s-spends-4-billion-a-year-subsidizing-stalinist-style-domestic-sugar-production/
2023: 0.70272% of GDP (World Bank) 2024: CHF 5.95 billion official military spending When including militia system costs: 1% GDP (CHF 8.75B) Comparison: Near bottom in Europe; only Ireland, Malta, Moldova spend less (excluding microstates with no armies) Additional sources: https://data.worldbank.org/indicator/MS.MIL.XPND.GD.ZS?locations=CH | https://www.avenir-suisse.ch/en/blog-defence-spending-switzerland-is-in-better-shape-than-it-seems/ | https://tradingeconomics.com/switzerland/military-expenditure-percent-of-gdp-wb-data.html
2024 GDP per capita (PPP-adjusted): Switzerland $93,819 vs United States $75,492 Switzerland’s GDP per capita 24% higher than US when adjusted for purchasing power parity Nominal 2024: Switzerland $103,670 vs US $85,810 Additional sources: https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=CH | https://tradingeconomics.com/switzerland/gdp-per-capita-ppp | https://www.theglobaleconomy.com/USA/gdp_per_capita_ppp/
OECD government spending data shows significant variation among developed nations: United States: 38.0% of GDP (2023) Switzerland: 35.0% of GDP - 3 percentage points lower than US Singapore: 15.0% of GDP - 23 percentage points lower than US (per IMF data) OECD average: approximately 40% of GDP Additional sources: https://data.oecd.org/gga/general-government-spending.htm
Chance of American dying in foreign-born terrorist attack: 1 in 3.6 million per year (1975-2015) Including 9/11 deaths; annual murder rate is 253x higher than terrorism death rate More likely to die from lightning strike than foreign terrorism Note: Comprehensive 41-year study shows terrorism risk is extremely low compared to everyday dangers Additional sources: https://www.cato.org/policy-analysis/terrorism-immigration-risk-analysis | https://www.nbcnews.com/news/us-news/you-re-more-likely-die-choking-be-killed-foreign-terrorists-n715141
The total number of embryos affected by the use of thalidomide during pregnancy is estimated at 10,000, of whom about 40% died around the time of birth. More than 10,000 children in 46 countries were born with deformities such as phocomelia. Additional sources: https://en.wikipedia.org/wiki/Thalidomide_scandal
Study of thalidomide survivors documenting ongoing disability impacts, quality of life, and long-term health outcomes. Survivors (now in their 60s) continue to experience significant disability from limb deformities, organ damage, and other effects. Additional sources: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0210222
US Census Bureau historical estimates of world population by country and region (1950-2050). US population in 1960: 180 million of 3 billion worldwide (6%). Additional sources: https://www.census.gov/data/tables/time-series/demo/international-programs/historical-est-worldpop.html
Overall, the 138 clinical trials had an estimated median (IQR) cost of $19.0 million ($12.2 million-$33.1 million)... The clinical trials cost a median (IQR) of $41,117 ($31,802-$82,362) per patient. Additional sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6248200/
Disability weights for 235 health states used in Global Burden of Disease calculations. Weights range from 0 (perfect health) to 1 (death equivalent). Chronic conditions like diabetes (0.05-0.35), COPD (0.04-0.41), depression (0.15-0.66), and cardiovascular disease (0.04-0.57) show substantial variation by severity. Treatment typically reduces disability weights by 50-80 percent for manageable chronic conditions.
Chronic diseases account for 90% of U.S. healthcare spending ( $3.7T/year). Additional sources: https://www.cdc.gov/chronic-disease/data-research/facts-stats/index.html
US GDP reached $28.78 trillion in 2024, representing approximately 26% of global GDP. Additional sources: https://data.worldbank.org/indicator/NY.GDP.MKTP.CD?locations=US | https://www.bea.gov/news/2024/gross-domestic-product-fourth-quarter-and-year-2024-advance-estimate
.
112.
Environmental Working Group. US farm subsidy database and analysis. Environmental Working Grouphttps://farm.ewg.org/ (2024)
US agricultural subsidies total approximately $30 billion annually, but create much larger economic distortions. Top 10% of farms receive 78% of subsidies, benefits concentrated in commodity crops (corn, soy, wheat, cotton), environmental damage from monoculture incentivized, and overall deadweight loss estimated at $50-120 billion annually. Additional sources: https://farm.ewg.org/ | https://www.ers.usda.gov/topics/farm-economy/farm-sector-income-finances/government-payments-the-safety-net/
Since 1971, the war on drugs has cost the United States an estimated $1 trillion in enforcement. The federal drug control budget was $41 billion in 2022. Mass incarceration costs the U.S. at least $182 billion every year, with over $450 billion spent to incarcerate individuals on drug charges in federal prisons.
Globally, fossil fuel subsidies were $7 trillion in 2022 or 7.1 percent of GDP. The United States subsidies totaled $649 billion. Underpricing for local air pollution costs and climate damages are the largest contributor, accounting for about 30 percent each.
The US spent approximately twice as much as other high-income countries on medical care (mean per capita: $9,892 vs $5,289), with similar utilization but much higher prices. Administrative costs accounted for 8% of US spending vs 1-3% in other countries. US spending on pharmaceuticals was $1,443 per capita vs $749 elsewhere. Despite spending more, US health outcomes are not better. Additional sources: https://jamanetwork.com/journals/jama/article-abstract/2674671
We quantify the amount of spatial misallocation of labor across US cities and its aggregate costs. Tight land-use restrictions in high-productivity cities like New York, San Francisco, and Boston lowered aggregate US growth by 36% from 1964 to 2009. Local constraints on housing supply have had enormous effects on the national economy. Additional sources: https://www.aeaweb.org/articles?id=10.1257/mac.20170388
Accounting for all the 2025 US tariffs and retaliation implemented to date, the level of real GDP is persistently -0.6% smaller in the long run, the equivalent of $160 billion 2024$ annually.
Americans will spend over 7.9 billion hours complying with IRS tax filing and reporting requirements in 2024. This costs the economy roughly $413 billion in lost productivity. In addition, the IRS estimates that Americans spend roughly $133 billion annually in out-of-pocket costs, bringing the total compliance costs to $546 billion, or nearly 2 percent of GDP.
Heart failure alone: $108 billion/year (2012 global analysis, 197 countries) US CVD: $555B (2016) → projected $1.8T by 2050 LMICs total CVD loss: $3.7T cumulative (2011-2015, 5-year period) CVD is costliest disease category in most developed nations Note: No single $2.1T global figure found; estimates vary widely by scope and year Additional sources: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001258
US life expectancy at birth was 77.5 years in 2023 Male life expectancy: 74.8 years Female life expectancy: 80.2 years This is 6-7 years lower than peer developed nations despite higher healthcare spending Additional sources: https://www.cdc.gov/nchs/fastats/life-expectancy.htm
US median household income was $77,500 in 2023 Real median household income declined 0.8% from 2022 Gini index: 0.467 (income inequality measure) Additional sources: https://www.census.gov/library/publications/2024/demo/p60-282.html
US military spending in constant 2024 dollars: 1939 $29B (pre-WW2 baseline), 1940 $37B, 1944 $1,383B, 1945 $1,420B (peak), 1946 $674B, 1947 $176B, 1948 $117B, 2024 $886B. The post-WW2 demobilization cut spending 88% in two years (1945-1947). Current peacetime spending ($886B) is 30x the pre-WW2 baseline and 62% of peak WW2 spending, in inflation-adjusted dollars.
U.S. military spending amounted to 3.5% of GDP in 2024. In 2024, the U.S. spent nearly $1 trillion on its military budget, equal to 3.4% of GDP. Additional sources: https://www.statista.com/statistics/262742/countries-with-the-highest-military-spending/ | https://www.sipri.org/sites/default/files/2025-04/2504_fs_milex_2024.pdf
73.6% (or 174 million people) of the citizen voting-age population was registered to vote in 2024 (Census Bureau). More than 211 million citizens were active registered voters (86.6% of citizen voting age population) according to the Election Assistance Commission. Additional sources: https://www.census.gov/newsroom/press-releases/2025/2024-presidential-election-voting-registration-tables.html | https://www.eac.gov/news/2025/06/30/us-election-assistance-commission-releases-2024-election-administration-and-voting
The Constitution provides that the president ’shall have Power, by and with the Advice and Consent of the Senate, to make Treaties, provided two-thirds of the Senators present concur’ (Article II, section 2). Treaties are formal agreements with foreign nations that require two-thirds Senate approval. 67 senators (two-thirds of 100) must vote to ratify a treaty for it to take effect. Additional sources: https://www.senate.gov/about/powers-procedures/treaties.htm
Presidential candidates raised $2 billion; House and Senate candidates raised $3.8 billion and spent $3.7 billion; PACs raised $15.7 billion and spent $15.5 billion. Total federal campaign spending approximately $20 billion. Additional sources: https://www.fec.gov/updates/statistical-summary-of-24-month-campaign-activity-of-the-2023-2024-election-cycle/
Total federal lobbying reached record $4.4 billion in 2024. The $150 million increase in lobbying continues an upward trend that began in 2016. Additional sources: https://www.opensecrets.org/news/2025/02/federal-lobbying-set-new-record-in-2024/
National average: 1 in 60 million chance (2008 election analysis by Gelman, Silver, Edlin) Swing states (NM, VA, NH, CO): 1 in 10 million chance Non-competitive states: 34 states >1 in 100 million odds; 20 states >1 in 1 billion Washington DC: 1 in 490 billion odds Methodology: Probability state is necessary for electoral college win × probability state vote is tied Additional sources: https://sites.stat.columbia.edu/gelman/research/published/probdecisive2.pdf | https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1465-7295.2010.00272.x
The overall failure rate of drugs that passed into Phase 1 trials to final approval is 90%. This lack of translation from promising preclinical findings to success in human trials is known as the "valley of death." Estimated 30-50% of promising compounds never proceed to Phase 2/3 trials primarily due to funding barriers rather than scientific failure. The late-stage attrition rate for oncology drugs is as high as 70% in Phase II and 59% in Phase III trials.
Current VSL (2024): $13.7 million (updated from $13.6M) Used in cost-benefit analyses for transportation regulations and infrastructure Methodology updated in 2013 guidance, adjusted annually for inflation and real income VSL represents aggregate willingness to pay for safety improvements that reduce fatalities by one Note: DOT has published VSL guidance periodically since 1993. Current $13.7M reflects 2024 inflation/income adjustments Additional sources: https://www.transportation.gov/office-policy/transportation-policy/revised-departmental-guidance-on-valuation-of-a-statistical-life-in-economic-analysis | https://www.transportation.gov/regulations/economic-values-used-in-analysis
India: $23-$50 per DALY averted (least costly intervention, $1,000-$6,100 per death averted) Sub-Saharan Africa (2022): $220-$860 per DALY (Burkina Faso: $220, Kenya: $550, Nigeria: $860) WHO estimates for Africa: $40 per DALY for fortification, $255 for supplementation Uganda fortification: $18-$82 per DALY (oil: $18, sugar: $82) Note: Wide variation reflects differences in baseline VAD prevalence, coverage levels, and whether intervention is supplementation or fortification Additional sources: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0012046 | https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0266495
The $50,000/QALY threshold is widely used in US health economics literature, originating from dialysis cost benchmarks in the 1980s. In US cost-utility analyses, 77.5% of authors use either $50,000 or $100,000 per QALY as reference points. Most successful health programs cost $3,000-10,000 per QALY. WHO-CHOICE uses GDP per capita multiples (1× GDP/capita = "very cost-effective", 3× GDP/capita = "cost-effective"), which for the US ( $70,000 GDP/capita) translates to $70,000-$210,000/QALY thresholds. Additional sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC5193154/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9278384/
78.4% of U.S. employees have at least one chronic condition (7% increase since 2021) 58% of employees report physical chronic health conditions 28% of all employees experience productivity loss due to chronic conditions Average productivity loss: $4,798 per employee per year Employees with 3+ chronic conditions miss 7.8 days annually vs 2.2 days for those without Note: 28% productivity loss translates to roughly 11 hours per week (28% of 40-hour workweek) Additional sources: https://www.ibiweb.org/resources/chronic-conditions-in-the-us-workforce-prevalence-trends-and-productivity-impacts | https://www.onemedical.com/mediacenter/study-finds-more-than-half-of-employees-are-living-with-chronic-conditions-including-1-in-3-gen-z-and-millennial-employees/ | https://debeaumont.org/news/2025/poll-the-toll-of-chronic-health-conditions-on-employees-and-workplaces/
.
137.
Olson, M. The Logic of Collective Action: Public Goods and the Theory of Groups. (Harvard University Press, Cambridge, MA, 1965).
Government spending is optimized for lobbying intensity, not net societal value. Programs with 100:1 benefit-cost ratios get billions while programs with negative returns get hundreds of billions. Incentive Alignment Bonds flip this by creating a capital pool that rewards politicians (via campaign support and post-office opportunities) for funding high-NSV programs over low-NSV alternatives. The result: public good becomes private profit for both investors and elected officials.
Reviews the $1.5 billion pilot Advance Market Commitment for pneumococcal vaccine. Three vaccines developed, 150 million children immunized, estimated 700,000 lives saved. Discusses AMC design for well-defined products versus systemic reform.
What’s the maximum cost to achieve any policy change through legal democratic channels? $25B for the US, $200B globally. For high-value reforms like military-to-health reallocation, this yields ROI exceeding 400,000:1.
Thousands of jurisdictions have made different policy and budget choices over decades, creating a natural experiment. Optimocracy applies causal inference to this cross-jurisdictional time-series data to identify which policies predict above-average median income and healthy life years. It then publishes evidence-based recommendations for every major vote, tracks politician alignment, and funds aligned candidates via SuperPAC, making suboptimal policy politically expensive while preserving democratic structures.
The Optimal Policy Generator (OPG) produces systematic public policy recommendations for jurisdictions at any level (country, state, city), generating prioritized enact/replace/repeal/maintain recommendations to maximize real after-tax median income growth and median healthy life years, based on quasi-experimental evidence from centuries of policy variation data.
143.
Value captured by 1% treaty of $27+ billion annually.
A 1% treaty redirects 1% of global military spending ($2.7T × 1% = $27.2B) to pragmatic clinical trials, with 10% of this flow (2.7B annually) distributed to VICTORY Incentive Alignment Bondholders as returns.
Only 15 diseases/year get their first treatment each year. With 6.65 thousand diseases lacking effective treatments, the backlog would take 443 years to clear. Integrating pragmatic trials into standard healthcare increases trial capacity 12.3x, cutting that timeline from 443 years to 36 years. The average untreated disease gets a treatment 212 years earlier, saving 10.7 billion deaths at $0.842 per year of healthy life saved.
We present the Predictor Impact Score (PIS), a novel composite metric operationalizing Bradford Hill causality criteria for automated signal detection from aggregated N-of-1 observational studies. Combined with pragmatic trial confirmation (based on evidence from 108+ embedded trials), this two-stage framework would generate validated outcome labels at 44.1x lower cost than traditional Phase III trials. This enables continuous, population-scale pharmacovigilance and precision dosing recommendations.
After proving a drug is safe, the FDA requires 8.2 years to prove it works before patients can access it. We estimate this delay cost 102 million deaths among people waiting for approved drugs (1962-2024). The human cost in death and disability of blocking good drugs is 3.07k higher than the cost of approving bad ones.
Representative democracy suffers from an inescapable principal-agent problem where elected officials’ incentives diverge from citizen welfare. Wishocracy introduces RAPPA (Randomized Aggregated Pairwise Preference Allocation), which aggregates citizen preferences through cognitively tractable pairwise comparisons and creates accountability via Citizen Alignment Scores that channel electoral resources toward politicians who actually represent what citizens want.
Systems audit estimating an annual U.S. efficiency gap of $4.9T, with $2.45T recoverable at OECD-median performance across direct spending waste, compliance burden, policy-induced GDP loss, and system inefficiency.
The Optimal Budget Generator (OBG) uses causal inference, diminishing returns modeling, and cost-effectiveness evidence to determine optimal public goods funding levels that maximize two welfare metrics: real after-tax median income growth and median healthy life years. For each spending category, OBG estimates an Optimal Spending Level (OSL) and produces a gap analysis showing where current government budgets are over- or underfunded relative to evidence-based benchmarks. The Budget Impact Score (BIS) measures confidence in each recommendation based on the quality of causal evidence.
6.65 thousand diseases have zero FDA-approved treatments; at current trial capacity, exploring them takes 443 years. Redirecting 1% of military spending scales capacity 12.3x, cutting the timeline to 36 years and preventing 10.7 billion deaths. At $0.00177/DALY, 50.3kx more cost-effective than the best existing interventions. Incentive Alignment Bonds make adoption politically viable.
